#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3404	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2417	417.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1841	1841	T	476	T,A	420,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3404	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2417	417.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1575	1575	C	523	C,A	423,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5810	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3974	438.1	0	.	n	.	0	T695C	SNP	695	695	T	1232	1232	C	457	C,A	367,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5810	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3974	438.1	0	.	n	.	0	G1365A	SNP	1365	1365	G	1902	1902	A	486	A	394	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5810	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3974	438.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2508	2508	C	534	C,A	429,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5810	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3974	438.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2582	2582	A	539	A	430	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5810	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3974	438.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3134	3134	C	519	C,T	434,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5810	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3974	438.1	0	HET	.	.	.	C1075T,A	.	1075	1075	C	1612	1612	C	456	C,T,A	271,100,2	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	518	folP	852	852	99.77	folP.l15.c4.ctg.1	1942	79.8	0	.	p	.	0	S68P	NONSYN	202	204	TCG	754	756	CCG	108;108;107	C;C;G,C	91;91;86,1	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	518	folP	852	852	99.77	folP.l15.c4.ctg.1	1942	79.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1234	1236	AGC	99;99;99	A,G;G,A;C	80,1;81,1;78	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1048	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3718	84.4	1	SNP	p	S91F	0	.	.	271	273	TCC	756	758	TCC	86;85;85	T;C;C	66;69;69	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1048	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3718	84.4	1	SNP	p	D95G	0	.	.	283	285	GAC	768	770	GAC	86;83;83	G;A;C	66;67;69	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1048	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3718	84.4	1	SNP	p	D95N	0	.	.	283	285	GAC	768	770	GAC	86;83;83	G;A;C	66;67;69	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	558	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1790	93.6	0	.	p	.	0	R2fs	FSHIFT	4	4	A	538	538	A	127	A	93	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	300	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1278	70.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1004	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3234	92.8	1	SNP	p	D86N	0	.	.	256	258	GAC	691	693	GAC	106;106;106	G;A;C	78;79;83	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1004	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3234	92.8	1	SNP	p	S87W	0	.	.	259	261	AGT	694	696	AGT	106;106;106	A;G;T	78;81;78	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1004	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3234	92.8	1	SNP	p	S87I	0	.	.	259	261	AGT	694	696	AGT	106;106;106	A;G;T	78;81;78	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1004	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3234	92.8	1	SNP	p	S87R	0	.	.	259	261	AGT	694	696	AGT	106;106;106	A;G;T	78;81;78	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1004	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3234	92.8	1	SNP	p	S88P	0	.	.	262	264	TCC	697	699	TCC	105;105;105	T,G;C;C	80,1;81;82	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	924	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3116	88.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1782	1784	GGC	109;108;107	G;G;C	94;91;91	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1457	1459	GCA	119;120;121	G,A;C;A	95,1;95;98	penA.4.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1460	1462	ATC	122;122;122	A;T,A;C,A	98;95,1;101,1	penA.4.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1472	1474	GTG	125;126;125	G,T;T,G;G	102,1;91,2;97	penA.4.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1472	1474	GTG	125;126;125	G,T;T,G;G	102,1;91,2;97	penA.4.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1976	1978	ACC	101;102;103	A;C;C	88;89;90	penA.4.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2030	2032	GCG	99;99;98	G;C;G	81;73;78	penA.4.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2030	2032	GCG	99;99;98	G;C;G	81;73;78	penA.4.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2153	2155	AGC	96;94;96	A,C;G;C	75,1;77;78	penA.4.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2162	2164	GGC	96;96;96	G,C;G;C	78,2;82;77	penA.4.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.4.001	penA.4.001	1	1	27	854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2789	91.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2180	2182	CCG	99;100;97	C;C;G	72;80;71	penA.4.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1258	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3569	105.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1865	1867	CCG	114;114;114	C;C;G	91;93;92	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	636	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2185	87.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	822	822	C	95	C	80	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	170	90.23	porB1a.l15.c4.ctg.1	1411	18.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1266	1268	AAT	6;6;6	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	170	90.23	porB1a.l15.c4.ctg.1	1411	18.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1269	1271	AAT	6;5;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	170	90.23	porB1a.l15.c4.ctg.1	1411	18.7	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1281	1283	GTT	4;4;4	G;T;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	170	90.23	porB1a.l15.c4.ctg.1	1411	18.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1293	1295	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	170	90.23	porB1a.l15.c4.ctg.1	1411	18.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1316	1318	GTA	4;4;4	G;T;A	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	170	90.23	porB1a.l15.c4.ctg.1	1411	18.7	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1328	1328	G	4	G	4	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	904	906	AAG	147;147;146	A,C;A;G,T	112,1;113;115,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1180	1182	GAT	123;123;121	G;A;T	105;104;98	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1183	1185	GGT	120;119;118	G;G;T	101;103;100	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	0	.	p	.	0	V215D	NONSYN	643	645	GTT	1189	1191	GAT	116;117;120	G;A;T	96;96;99	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1198	1200	ATG	118;118;119	A;T;G	102;95;101	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1315	1317	ACG	109;108;108	A;C;G	91;86;88	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1321	1323	GTT	104;104;103	G;T;T,G	87;86;84,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1435	1437	AAC	112;112;111	A;A;C	92;91;90	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	1	SNP	p	A121D	1	.	.	361	363	GAC	907	909	GAC	146;146;147	G;A;C	111;113;116	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	664	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1924	101.8	1	SNP	p	D121N	0	.	.	361	363	GAC	907	909	GAC	146;146;147	G;A;C	111;113;116	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2236	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5343	125.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2272	2274	CAT	103;103;103	C;A;T	90;85;86	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	394	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1222	95.9	1	SNP	p	V57M	1	.	.	169	171	ATG	621	623	ATG	159;159;160	A;T;G	131;130;126	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	2776	tetM	1920	1920	100.0	tetM.l6.c4.ctg.1	2944	282.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
